AstraZeneca Plc is to invest $570 million in infrastructure in Canada with the goal of executing more than 210 global clinical studies in the country. Announced on 23 January, the investment accelerates a move to place Canada on its map as a centre for global clinical development activity. It follows the UK company’s acquisition in 2024 of Fusion Pharmaceuticals Inc, a Canadian biopharmaceutical company developing alpha-particle radiotherapeutics for cancer. The acquisition of Fusion was completed last year for C$3 billion ($2.09 billion).
